SARTORIUS STEDIM BIOTECH (56S1.DE) Stock Fundamental Analysis
FRA:56S1 - Deutsche Boerse Ag - FR0013154002 - Common Stock - Currency: EUR
Taking everything into account, 56S1 scores 5 out of 10 in our fundamental rating. 56S1 was compared to 19 industry peers in the Life Sciences Tools & Services industry. Both the profitability and the financial health of 56S1 get a neutral evaluation. Nothing too spectacular is happening here. While showing a medium growth rate, 56S1 is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
56S1 had positive earnings in the past year.
56S1 had a positive operating cash flow in the past year.
In the past 5 years 56S1 has always been profitable.
In the past 5 years 56S1 always reported a positive cash flow from operatings.
1.2 Ratios
56S1 has a Return On Assets of 2.46%. This is comparable to the rest of the industry: 56S1 outperforms 57.89% of its industry peers.
With a Return On Equity value of 5.14%, 56S1 perfoms like the industry average, outperforming 57.89% of the companies in the same industry.
With a Return On Invested Capital value of 4.36%, 56S1 perfoms like the industry average, outperforming 42.11% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for 56S1 is above the industry average of 7.38%.
The 3 year average ROIC (10.41%) for 56S1 is well above the current ROIC(4.36%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.46% | ||
| ROE | 5.14% | ||
| ROIC | 4.36% |
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
1.3 Margins
56S1's Profit Margin of 7.15% is fine compared to the rest of the industry. 56S1 outperforms 73.68% of its industry peers.
In the last couple of years the Profit Margin of 56S1 has declined.
Looking at the Operating Margin, with a value of 14.05%, 56S1 is in line with its industry, outperforming 57.89% of the companies in the same industry.
In the last couple of years the Operating Margin of 56S1 has declined.
Looking at the Gross Margin, with a value of 43.89%, 56S1 is in the better half of the industry, outperforming 68.42% of the companies in the same industry.
56S1's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 14.05% | ||
| PM (TTM) | 7.15% | ||
| GM | 43.89% |
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
2. Health
2.1 Basic Checks
56S1 has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
56S1 has more shares outstanding than it did 1 year ago.
The number of shares outstanding for 56S1 has been increased compared to 5 years ago.
Compared to 1 year ago, 56S1 has an improved debt to assets ratio.
2.2 Solvency
56S1 has an Altman-Z score of 4.00. This indicates that 56S1 is financially healthy and has little risk of bankruptcy at the moment.
56S1 has a better Altman-Z score (4.00) than 78.95% of its industry peers.
The Debt to FCF ratio of 56S1 is 5.03, which is a neutral value as it means it would take 56S1, 5.03 years of fcf income to pay off all of its debts.
56S1 has a Debt to FCF ratio of 5.03. This is comparable to the rest of the industry: 56S1 outperforms 52.63% of its industry peers.
A Debt/Equity ratio of 0.72 indicates that 56S1 is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.72, 56S1 is not doing good in the industry: 68.42% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.72 | ||
| Debt/FCF | 5.03 | ||
| Altman-Z | 4 |
ROIC/WACC0.51
WACC8.53%
2.3 Liquidity
A Current Ratio of 1.85 indicates that 56S1 should not have too much problems paying its short term obligations.
56S1 has a better Current ratio (1.85) than 73.68% of its industry peers.
56S1 has a Quick Ratio of 1.14. This is a normal value and indicates that 56S1 is financially healthy and should not expect problems in meeting its short term obligations.
56S1 has a better Quick ratio (1.14) than 63.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.85 | ||
| Quick Ratio | 1.14 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 4.97% over the past year.
56S1 shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 4.19% yearly.
56S1 shows a small growth in Revenue. In the last year, the Revenue has grown by 5.21%.
56S1 shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.05% yearly.
EPS 1Y (TTM)4.97%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%34.88%
Revenue 1Y (TTM)5.21%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%11.65%
3.2 Future
The Earnings Per Share is expected to grow by 21.45% on average over the next years. This is a very strong growth
Based on estimates for the next years, 56S1 will show a quite strong growth in Revenue. The Revenue will grow by 10.39% on average per year.
EPS Next Y23.98%
EPS Next 2Y25.51%
EPS Next 3Y24.81%
EPS Next 5Y21.45%
Revenue Next Year8.49%
Revenue Next 2Y9.67%
Revenue Next 3Y10.37%
Revenue Next 5Y10.39%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 52.84 indicates a quite expensive valuation of 56S1.
Compared to the rest of the industry, the Price/Earnings ratio of 56S1 indicates a slightly more expensive valuation: 56S1 is more expensive than 68.42% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 27.30. 56S1 is valued rather expensively when compared to this.
The Price/Forward Earnings ratio is 36.42, which means the current valuation is very expensive for 56S1.
Based on the Price/Forward Earnings ratio, 56S1 is valued a bit more expensive than the industry average as 73.68% of the companies are valued more cheaply.
When comparing the Price/Forward Earnings ratio of 56S1 to the average of the S&P500 Index (21.76), we can say 56S1 is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 52.84 | ||
| Fwd PE | 36.42 |
4.2 Price Multiples
56S1's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. 56S1 is more expensive than 73.68% of the companies in the same industry.
56S1's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 33.49 | ||
| EV/EBITDA | 30.6 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
56S1's earnings are expected to grow with 24.81% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.2
PEG (5Y)12.6
EPS Next 2Y25.51%
EPS Next 3Y24.81%
5. Dividend
5.1 Amount
With a yearly dividend of 0.34%, 56S1 is not a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 0.72, 56S1 is paying slightly less dividend.
With a Dividend Yield of 0.34, 56S1 pays less dividend than the S&P500 average, which is at 2.37.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.34% |
5.2 History
The dividend of 56S1 has a limited annual growth rate of 4.44%.
Dividend Growth(5Y)4.44%
Div Incr Years0
Div Non Decr Years1
5.3 Sustainability
32.84% of the earnings are spent on dividend by 56S1. This is a low number and sustainable payout ratio.
56S1's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP32.84%
EPS Next 2Y25.51%
EPS Next 3Y24.81%
FRA:56S1 (7/9/2025, 7:00:00 PM)
200.8
+1.6 (+0.8%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners10.65%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap19.54B
Analysts77.78
Price Target236.96 (18.01%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.34% |
Yearly Dividend0.71
Dividend Growth(5Y)4.44%
DP32.84%
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.91%
Min EPS beat(2)7.63%
Max EPS beat(2)22.18%
EPS beat(4)2
Avg EPS beat(4)0.98%
Min EPS beat(4)-20.27%
Max EPS beat(4)22.18%
EPS beat(8)2
Avg EPS beat(8)-16.9%
EPS beat(12)2
Avg EPS beat(12)-16.88%
EPS beat(16)5
Avg EPS beat(16)-11.85%
Revenue beat(2)2
Avg Revenue beat(2)3.21%
Min Revenue beat(2)2.91%
Max Revenue beat(2)3.52%
Revenue beat(4)3
Avg Revenue beat(4)0.7%
Min Revenue beat(4)-5.11%
Max Revenue beat(4)3.52%
Revenue beat(8)4
Avg Revenue beat(8)-1.35%
Revenue beat(12)4
Avg Revenue beat(12)-1.7%
Revenue beat(16)8
Avg Revenue beat(16)12.23%
PT rev (1m)-4.61%
PT rev (3m)-7.03%
EPS NQ rev (1m)2.28%
EPS NQ rev (3m)2.86%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.49%
Revenue NQ rev (1m)-1.34%
Revenue NQ rev (3m)-5.02%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.05%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 52.84 | ||
| Fwd PE | 36.42 | ||
| P/S | 6.84 | ||
| P/FCF | 33.49 | ||
| P/OCF | 22.22 | ||
| P/B | 4.92 | ||
| P/tB | N/A | ||
| EV/EBITDA | 30.6 |
EPS(TTM)3.8
EY1.89%
EPS(NY)5.51
Fwd EY2.75%
FCF(TTM)6
FCFY2.99%
OCF(TTM)9.04
OCFY4.5%
SpS29.36
BVpS40.81
TBVpS-5.43
PEG (NY)2.2
PEG (5Y)12.6
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.46% | ||
| ROE | 5.14% | ||
| ROCE | 5.47% | ||
| ROIC | 4.36% | ||
| ROICexc | 4.84% | ||
| ROICexgc | 15.14% | ||
| OM | 14.05% | ||
| PM (TTM) | 7.15% | ||
| GM | 43.89% | ||
| FCFM | 20.42% |
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
ROICexc(3y)10.84%
ROICexc(5y)15.37%
ROICexgc(3y)26.31%
ROICexgc(5y)36.49%
ROCE(3y)13.07%
ROCE(5y)18.3%
ROICexcg growth 3Y-36.77%
ROICexcg growth 5Y-16.49%
ROICexc growth 3Y-43.34%
ROICexc growth 5Y-25.09%
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
F-Score7
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.72 | ||
| Debt/FCF | 5.03 | ||
| Debt/EBITDA | 4 | ||
| Cap/Depr | 95.85% | ||
| Cap/Sales | 10.35% | ||
| Interest Coverage | 2.25 | ||
| Cash Conversion | 123.84% | ||
| Profit Quality | 285.66% | ||
| Current Ratio | 1.85 | ||
| Quick Ratio | 1.14 | ||
| Altman-Z | 4 |
F-Score7
WACC8.53%
ROIC/WACC0.51
Cap/Depr(3y)182.98%
Cap/Depr(5y)186.68%
Cap/Sales(3y)13.87%
Cap/Sales(5y)12.23%
Profit Quality(3y)126.76%
Profit Quality(5y)109.63%
High Growth Momentum
Growth
EPS 1Y (TTM)4.97%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%34.88%
EPS Next Y23.98%
EPS Next 2Y25.51%
EPS Next 3Y24.81%
EPS Next 5Y21.45%
Revenue 1Y (TTM)5.21%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%11.65%
Revenue Next Year8.49%
Revenue Next 2Y9.67%
Revenue Next 3Y10.37%
Revenue Next 5Y10.39%
EBIT growth 1Y-0.84%
EBIT growth 3Y-23.35%
EBIT growth 5Y2.67%
EBIT Next Year91.76%
EBIT Next 3Y37.04%
EBIT Next 5Y27.34%
FCF growth 1Y325.99%
FCF growth 3Y7.94%
FCF growth 5Y22.24%
OCF growth 1Y45.08%
OCF growth 3Y5.11%
OCF growth 5Y21.32%